Previous reports have established that p53 mutation data can be used as a predictive marker for cancer development in Barrett's patients (Schneider et al, 1996), and that the presence of p53 mutations can predict poor 5-year survival rates of Barrett's tumour patients postoperatively (Schneider et al, 2000). Here, TP53 is linked to cancer.